导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | - | 2421/4773 |
| 近一周 | -1.94% | 3160/5465 |
| 近一月 | -4.57% | 3327/5421 |
| 近一季 | -6.42% | 2403/5231 |
| 近半年 | 1.10% | 1216/4920 |
| 近一年 | 3.61% | 2037/4394 |
| 近两年 | 49.54% | 1514/2954 |
| 近三年 | 33.23% | 962/2253 |
| 成立以来 | 191.51% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.47% 3634/4961 |
15.95% 1616/5312 |
- - |
- - |
| 2025 | 22.62% 1952/4813 |
0.35% 1895/3635 |
2.82% 1333/4076 |
18.93% 2223/4524 |
-0.07% 2342/4813 |
| 2024 | 14.68% 1026/3463 |
2.36% 790/2808 |
-0.43% 763/3014 |
15.36% 1739/3129 |
-2.47% 2097/3463 |
| 2023 | -13.78% 1560/2656 |
2.67% 1320/2280 |
-5.78% 1532/2385 |
-5.70% 1360/2515 |
-5.49% 1369/2655 |
| 2022 | -20.23% 946/2207 |
-16.11% 1103/1919 |
9.21% 293/2016 |
-13.26% 869/2113 |
0.37% 1505/2208 |
| 2021 | 1.16% 688/1822 |
-5.33% 915/1255 |
10.99% 411/1330 |
-4.43% 708/1466 |
0.74% 1069/1822 |
| 2020 | 47.05% 200/1250 |
-6.26% 475/1028 |
17.65% 366/1067 |
15.89% 187/1164 |
15.04% 237/1184 |
| 2019 | 38.97% 293/1092 |
25.51% 460/754 |
1.98% 103/804 |
2.10% 323/850 |
6.35% 622/918 |
| 2018 | -21.79% 221/834 |
- - |
- - |
- - |
-12.70% 474/691 |
| 2017 | 30.15% 59/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.47% 142/605 |
- - |
- - |
- - |
- - |
| 2015 | 7.53% 174/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华安沪深300增强C VS. 长安沪深300非周期A(740101) |